John Nuss - Sep 5, 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Chief Scientific Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Stock symbol
VTYX
Transactions as of
Sep 5, 2023
Transactions value $
-$323,960
Form type
4
Date filed
9/7/2023, 04:21 PM
Previous filing
Aug 4, 2023
Next filing
Oct 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Options Exercise $2K +10K +4.08% $0.20* 255K Sep 5, 2023 Direct
transaction VTYX Common Stock Sale -$225K -6.99K -2.74% $32.24 248K Sep 5, 2023 Direct F1, F2
transaction VTYX Common Stock Sale -$101K -3.01K -1.21% $33.41 245K Sep 5, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTYX Stock Option (right to buy) Options Exercise $0 -10K -59.6% $0.00 6.78K Sep 5, 2023 Common Stock 10K $0.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2022.
F2 Represents the weighted average share price of an aggregate total of 6,991 shares sold in the price range of $31.97 to $32.935. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 3,009 shares sold in the price range of $32.98 to $33.9549. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 1, 2020.